查看文章

Objectives

This study described healthcare resource utilization (HRU), costs, and treatment patterns among advanced or metastatic non-small cell lung cancer (a/mNSCLC) patients with different EGFRmutation types.

Methods

This retrospective cohort study identified patients with EGFR mutation test results in linked NeoGenomics and IQVIA PharMetrics® Plus databases between 01Jan2016 to 30Apr2021 (study period). Patients with evidence of a/mNSCLC between 01Jul2016 to 31Mar2021 (selection window) were included; date of first observed a/mNSCLC was the index date. All patients had a 6-month pre-index and≥ 1-month follow-up period. All-cause HRU, costs, and treatment patterns were reported among EGFR+ subgroups including exon 19 deletion (exon19del), exon 21 L858R (L858R), and exon 20 insertion (exon20i) patients.

Results

A total of 181 EGFR+ patients met selection criteria. Exon19del …